Immunovant, Inc. IMVT Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s total equity?
- Immunovant, Inc. (IMVT) reported total equity of $852.59M in Q1 2026.
- How has Immunovant, Inc.'s total equity changed year-over-year?
- Immunovant, Inc.'s total equity increased by 20.5% year-over-year, from $707.45M to $852.59M.
- What is the long-term trend for Immunovant, Inc.'s total equity?
- Over 5 years (2021 to 2026), Immunovant, Inc.'s total equity has grown at a 16.8% compound annual growth rate (CAGR), from $391.48M to $852.59M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.